Learn About Paramyotonia Congenita

What is the definition of Paramyotonia Congenita?

Paramyotonia congenita is a disorder that affects muscles used for movement (skeletal muscles). Beginning in infancy or early childhood, people with this condition experience bouts of sustained muscle tensing (myotonia) that prevent muscles from relaxing normally. Myotonia causes muscle stiffness that typically appears after exercise and can be induced by muscle cooling. This stiffness chiefly affects muscles in the face, neck, arms, and hands, although it can also affect muscles used for breathing and muscles in the lower body. Unlike many other forms of myotonia, the muscle stiffness associated with paramyotonia congenita tends to worsen with repeated movements.

What are the causes of Paramyotonia Congenita?

Mutations in the SCN4A gene cause paramyotonia congenita. This gene provides instructions for making a protein that is critical for the normal function of skeletal muscle cells. For the body to move normally, skeletal muscles must tense (contract) and relax in a coordinated way. Muscle contractions are triggered by the flow of positively charged atoms (ions), including sodium, into skeletal muscle cells. The SCN4A protein forms channels that control the flow of sodium ions into these cells.

How prevalent is Paramyotonia Congenita?

Paramyotonia congenita is an uncommon disorder; it is estimated to affect fewer than 1 in 100,000 people.

Is Paramyotonia Congenita an inherited disorder?

This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. In many cases, an affected person has one parent with the condition.

Who are the top Paramyotonia Congenita Local Doctors?
Elite in Paramyotonia Congenita
Elite in Paramyotonia Congenita

Office

355 W 16th St Ste 3200, 
Indianapolis, IN 
Languages Spoken:
English

Laurie Gutmann is a Neurologist in Indianapolis, Indiana. Dr. Gutmann is rated as an Elite provider by MediFind in the treatment of Paramyotonia Congenita. Her top areas of expertise are Paramyotonia Congenita, Myotonic Dystrophy Type 2, Myotonic Dystrophy, and Charcot-Marie-Tooth Disease.

Michele D. Nacouzi
Advanced in Paramyotonia Congenita
Family Medicine
Advanced in Paramyotonia Congenita
Family Medicine

Duke Primary Care Brier Creek

10208 Cerny St, 
Raleigh, NC 
Languages Spoken:
English, French, Spanish
Accepting New Patients
Offers Telehealth

Michele Nacouzi is a primary care provider, practicing in Family Medicine in Raleigh, North Carolina. Dr. Nacouzi is rated as an Advanced provider by MediFind in the treatment of Paramyotonia Congenita. Her top areas of expertise are Myotonic Dystrophy, Myotonic Dystrophy Type 2, Sitosterolemia, and Paramyotonia Congenita. Dr. Nacouzi is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Paramyotonia Congenita
Elite in Paramyotonia Congenita
Milan, IT 

Giovanni Meola practices in Milan, Italy. Mr. Meola is rated as an Elite expert by MediFind in the treatment of Paramyotonia Congenita. His top areas of expertise are Myotonic Dystrophy Type 2, Paramyotonia Congenita, Myotonic Dystrophy, Amyotonia Congenita, and Thymectomy.

What are the latest Paramyotonia Congenita Clinical Trials?
A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101 Administered to Participants With Myotonic Dystrophy Type 1

Summary: The primary purpose of the study is to evaluate the safety and tolerability of multiple intravenous (IV) doses of DYNE-101 administered to participants with Myotonic Dystrophy Type 1 (DM1). The study consists of 4 periods: A Screening Period (up to 8 weeks), a Placebo-Controlled Period (24 weeks), a Treatment Period (24 weeks) and a Long-Term Extension (LTE) Period (168 weeks) in both multiple-asc...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Who are the sources who wrote this article ?

Published Date: August 01, 2015
Published By: National Institutes of Health